IOZK receives manufacturing license for patient-specific tumor vaccine

The IOZK received the GMP certificate and official manufacturing authorization for the autologous tumor vaccine developed at the IOZK in combination with oncolytic viruses in accordance with the German Medicines Act for "novel therapies."